Evaluating Measures of Pre-ART Adherence Readiness Through Associations with ART Adherence in the Early Months of Treatment

被引:0
作者
Azhar, Gulrez Shah [1 ,2 ]
Schneider, Stefan [3 ]
Hoffman, Risa [4 ]
Gordon, Kyle [4 ]
Ramirez, Daniel [3 ]
Wagner, Glenn [2 ]
机构
[1] Pardee RAND Grad Sch, 1776 Main St, Santa Monica, CA 90401 USA
[2] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA
[3] Long Beach Educ & Res Consultants, Long Beach, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA
关键词
START; ART; Treatment readiness; Adherence; HIV; VALIDATION;
D O I
10.1007/s10461-019-02708-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Determining a patient's readiness to adhere well prior to the start of ART provides an opportunity to address adherence barriers before poor pill taking habits form, and ultimately improve clinical outcomes and resource utilization. Three methods of measuring adherence readiness and their comparative utility in predicting early ART adherence were examined in a sample of 176 patients preparing to start ART. Data were analyzed data from a randomized controlled trial of a cognitive-behavioral adherence intervention. Three measures of pre-ART adherence readiness (provider estimate, 1 week vitamin practice trials, and self-report [HIV Medication Readiness Scale; Transtheoretical Stages of Change item (TSOC)] were examined in association with measures of (1) ART initiation, (2) ART retention, (3) mean electronic dose-taking adherence, and (4) achievement of optimal (85+ % dose-taking) adherence, over the first 3 months of ART. Of the 176 patients, 166 (94.3%) started ART; 124 (74.7% of those who started ART; 70.5% of whole sample) completed the first 3 months of ART. Among the 124 still on ART at month 3, mean dose-taking adherence was 79.3%, and 62 (35.2% of whole sample) achieved optimal adherence. The provider estimate was the only readiness measure significantly associated with each of the four measures of early ART adherence, and it had the highest concordance statistics (71% PPV and 62.3% NPV) with optimal early ART adherence. Practice trial adherence was only associated with ART initiation and retention. Dose-taking adherence over 3 months was significantly correlated with the provider estimate and the two self-reports. Each method of early treatment adherence has its own utility, but the provider estimate had the best overall performance in predicting early ART adherence.
引用
收藏
页码:648 / 654
页数:7
相关论文
共 19 条
  • [1] AIDSinfo, 2019, GUID US ANT AG AD AD
  • [2] Development and validation of the HIV medication readiness scale
    Balfour, Louise
    Tasca, Giorgio A.
    Kowal, John
    Corace, Kimberly
    Cooper, Curtis L.
    Angel, Jonathan B.
    Garber, Gary
    MacPherson, Paul A.
    Cameron, D. William
    [J]. ASSESSMENT, 2007, 14 (04) : 408 - 416
  • [3] Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    Bangsberg, DR
    Hecht, FM
    Charlebois, ED
    Zolopa, AR
    Holodniy, M
    Sheiner, L
    Bamberger, JD
    Chesney, MA
    Moss, A
    [J]. AIDS, 2000, 14 (04) : 357 - 366
  • [4] Bangsberg DR, 2001, J ACQ IMMUN DEF SYND, V26, P435, DOI 10.1097/00126334-200104150-00005
  • [5] A learning theory perspective on lapse, relapse, and the maintenance of behavior change
    Bouton, ME
    [J]. HEALTH PSYCHOLOGY, 2000, 19 (01) : 57 - 63
  • [6] Grimes Richard M, 2013, J Int Assoc Provid AIDS Care, V12, P185, DOI 10.1177/1545109712454334
  • [7] Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy
    Gross, R
    Bilker, WB
    Friedman, HM
    Coyne, JC
    Strom, BL
    [J]. AIDS, 2002, 16 (13) : 1835 - 1837
  • [8] Development of stage of readiness and decisional balance instruments: Tools to enhance clinical decision-making for adherence to antiretroviral therapy
    Highstein, Gabrielle R.
    Willey, Cynthia
    Mundy, Linda M.
    [J]. AIDS AND BEHAVIOR, 2006, 10 (05) : 563 - 573
  • [9] Levels of Adherence Required for Virologic Suppression Among Newer Antiretroviral Medications
    Kobin, Allison Beth
    Sheth, Neha Umesh
    [J]. ANNALS OF PHARMACOTHERAPY, 2011, 45 (03) : 372 - 379
  • [10] Konkle-Parker D J, 2001, J Am Acad Nurse Pract, V13, P61, DOI 10.1111/j.1745-7599.2001.tb00219.x